One-year recombinant growth hormone therapy does not improve hemoglobin state and morphology of erythrocytes in growth hormone deficient children

Publication date: March 2018Source: Pathophysiology, Volume 25, Issue 1Author(s): Maria Pankratova, Alexander Yusipovich, Maria Vorontsova, Evgenia Parshina, Svetlana Bochkareva, Alexander Cherkashin, Adil Baizhumanov, Margarita Silicheva, Tatyana Shiryaeva, Georgy Maksimov, Valentina PeterkovaAbstractAn increase in growth rates of children suffering from growth hormone deficiency (GHD) subjected to recombinant growth hormone treatment (rGHT) was shown to be accompanied by acceleration of metabolic processes that may stimulate oxygen consumption in various organs and tissues. Therefore, oxygen-transporting properties of RBC should undergo considerable changes during the rGHT. The aim of this study was to examine the effects of rGHT on erythrocyte shape and hemoglobin state in GHD children. The level of oxyhemoglobin (Oxy-Hb) in RBC was analyzed by Raman spectroscopy. The RBC count, mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV) and other parameters were calculated. The blood of eleven treatment-naive prepubertal children with GHD (aged 3–9, median 5.7 years) was examined and compared with control group (aged 5–7; median 6.0 years) at three time points: 0, 3 and 12 months of rGHT. Before rGHT, the MI in GHD children was higher (median 0.48 vs 0.14 p = 0.0018) and the RBC count was lower (median 4.20 vs 4.96 1012 cells/L p = 0.0022) than in control group. After the treatment, cell count in GHD patients did not differ significantly from ...
Source: Pathophysiology - Category: Pathology Source Type: research